New clinical recommendation for local treatment of oligometastatic lung cancer.

Published Date: 26 Apr 2023

Regarding the use of definitive local therapy, including radiation, a new clinical guideline from the American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) offers recommendations.

Read Full News

Todays Updates


Planning Lung Cancer Screening, Surgery Between Clinicians and Patients Kevin Kunzmann


David Tom Cooke, MD, reviewed the importance of shared decision making as it relates to risk and benefit of cancer screening, as well as in more refined invasive care options.

Managing Perioperative, Postoperative Lung Cancer, with Joseph Friedberg, MD Joseph Friedberg, MD, Kevin Kunzmann


Friedberg explains how an emphasis on physical fitness prior to and after surgery can significantly better long-term outcomes.

Optimizing Lung Volume Reduction Surgery, with Charles Bakhos, MD, MBA, MS Charles Bakhos, MD, MBA, MS, Kevin Kunzmann


Bakhos explains the ideal patient population and strategies inherent to LVRS success.

NeuroVoices: Sneha Mantri, MD, MS, on Addressing Depression and Anxiety in Parkinson Care Marco Meglio


The chief medical officer at the Parkinson’s Foundation detailed how mood and behavioral symptoms shape quality of life in Parkinson disease and how clinicians can better identify and manage them.

Levacetylleucine Meets Primary and Secondary End Points in Phase 3 Ataxia-Telangiectasia Study Isabella Ciccone, MPH


IntraBio reported that levacetylleucine showed symptom improvement in the phase 3 IB1001-303 study for ataxia-telangiectasia, and it intends to proceed with regulatory submissions in multiple regions.

Migraine Medication Zavegepant Safe and Well Tolerated in Lactating Women, Phase 1 Study Shows Louie Pasculli


A Phase 1 study in healthy lactating women found that a single 10‑mg dose of zavegepant nasal spray was generally safe, well tolerated, and resulted in minimal infant exposure through breast milk.

Julie Khlevner, MD, AGAF, Reacts to the FDA Approval of Linaclotide for Pediatric IBS-C Julie Khlevner, MD, AGAF


Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

Todays Updates


Planning Lung Cancer Screening, Surgery Between Clinicians and Patients Kevin Kunzmann


David Tom Cooke, MD, reviewed the importance of shared decision making as it relates to risk and benefit of cancer screening, as well as in more refined invasive care options.

Managing Perioperative, Postoperative Lung Cancer, with Joseph Friedberg, MD Joseph Friedberg, MD, Kevin Kunzmann


Friedberg explains how an emphasis on physical fitness prior to and after surgery can significantly better long-term outcomes.

Optimizing Lung Volume Reduction Surgery, with Charles Bakhos, MD, MBA, MS Charles Bakhos, MD, MBA, MS, Kevin Kunzmann


Bakhos explains the ideal patient population and strategies inherent to LVRS success.

NeuroVoices: Sneha Mantri, MD, MS, on Addressing Depression and Anxiety in Parkinson Care Marco Meglio


The chief medical officer at the Parkinson’s Foundation detailed how mood and behavioral symptoms shape quality of life in Parkinson disease and how clinicians can better identify and manage them.

Levacetylleucine Meets Primary and Secondary End Points in Phase 3 Ataxia-Telangiectasia Study Isabella Ciccone, MPH


IntraBio reported that levacetylleucine showed symptom improvement in the phase 3 IB1001-303 study for ataxia-telangiectasia, and it intends to proceed with regulatory submissions in multiple regions.

Migraine Medication Zavegepant Safe and Well Tolerated in Lactating Women, Phase 1 Study Shows Louie Pasculli


A Phase 1 study in healthy lactating women found that a single 10‑mg dose of zavegepant nasal spray was generally safe, well tolerated, and resulted in minimal infant exposure through breast milk.

Julie Khlevner, MD, AGAF, Reacts to the FDA Approval of Linaclotide for Pediatric IBS-C Julie Khlevner, MD, AGAF


Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

World's premier cancer institute faces crippling cuts and chaos

2.

Patient Endured 9 Years of Chemotherapy for Cancer He Never Had

3.

Study reveals crucial gaps in oral cancer awareness in Middle East and North Africa

4.

In advanced endometrial cancer, immunocheckpoint inhibitor-chemotherapy combination improves overall survival.

5.

No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot